Real-World Persistence and Time to Next Treatment With Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke-Reference-Cited by-同舟云学术

Real-World Persistence and Time to Next Treatment With Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke

Published:2022-11 Issue:11 Volume:22 Page:e959-e971
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Narezkina Anna,Akhter Nausheen^ORCID,Lu Xiaoxiao,Emond Bruno^ORCID,Panjabi Sumeet,Forbes Shaun P.^ORCID,Hilts Annalise,Liu Stephanie,Lafeuille Marie-Hélène,Lefebvre Patrick,Huang Qing,Choi Michael

Funder

AbbVie

Janssen Scientific Affairs

Merck

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference51 articles.

1. Cancer statistics, 2020;Siegel;CA Cancer J Clin,2020

2. National Cancer Institute Surveillance, Epidemiology, and End Results Program;SEER Cancer Stat Facts: Chronic Lymphocytic Leukemia,2021

3. Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia;Thurmes;Leuk Lymphoma,2008